Literature DB >> 24388979

Targeting neurogenesis ameliorates danger assessment in a mouse model of Alzheimer's disease.

Adi Shruster1, Daniel Offen2.   

Abstract

Alzheimer's disease (AD) affects 13% of the population over the age of 65. Behavioral and neuropsychiatric symptoms are frequent and affect 80% of patients. Adult hippocampal neurogenesis, which is impaired in AD, is involved in learning and memory. It remains unclear, however, whether increasing adult neurogenesis improves behavioral symptoms in AD. We report that in the 3xTgAD mouse model of AD, chronic Wnt3a overexpression in the ventral hippocampus dentate gyrus (DG) restored adult neurogenesis to physiological levels. The restoration of adult neurogenesis led to full recovery of danger assessment impairment and the effect was blocked by ablation of neurogenesis with X-irradiation. Finally, using a bed nucleus of stria terminalis (BNST) mRNA expression array, we found that the expression of the 5-HT1A receptor in 3xTgAD mice is selectively decreased and normalized by Wnt3a overexpression in the ventral hippocampus DG, and this normalization is neurogenesis dependent. These findings indicate that reestablishing a functional population of hippocampal newborn neurons in adult AD mice rescues behavioral symptoms, suggesting that adult neurogenesis may be a promising therapeutic target for alleviating behavioral deficits in AD patients.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  5-HT(1A) receptor; Alzheimer's disease; Bed nucleus of stria terminalis; Behavioral and psychological symptoms; Neurogenesis; Wnt signaling

Mesh:

Substances:

Year:  2013        PMID: 24388979     DOI: 10.1016/j.bbr.2013.12.028

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  7 in total

1.  Mesenchymal stem cells can prevent alterations in behavior and neurogenesis induced by Aß25-35 administration.

Authors:  Keren Nicole Hamisha; Matanel Tfilin; Joseph Yanai; Gadi Turgeman
Journal:  J Mol Neurosci       Date:  2014-11-12       Impact factor: 3.444

Review 2.  Molecular Insights to the Wnt Signaling During Alzheimer's Disorder: a Potential Target for Therapeutic Interventions.

Authors:  Priyanka Nagu; Vivek Sharma; Tapan Behl; Amjad Khan A Pathan; Vineet Mehta
Journal:  J Mol Neurosci       Date:  2022-01-07       Impact factor: 3.444

3.  Red peppers with moderate and severe pungency prevent the memory deficit and hepatic insulin resistance in diabetic rats with Alzheimer's disease.

Authors:  Hye Jeong Yang; Dae Young Kwon; Min Jung Kim; Suna Kang; Na Rang Moon; James W Daily; Sunmin Park
Journal:  Nutr Metab (Lond)       Date:  2015-03-08       Impact factor: 4.169

4.  DNA polymerase β deficiency leads to neurodegeneration and exacerbates Alzheimer disease phenotypes.

Authors:  Peter Sykora; Magdalena Misiak; Yue Wang; Somnath Ghosh; Giovana S Leandro; Dong Liu; Jane Tian; Beverly A Baptiste; Wei-Na Cong; Boris M Brenerman; Evandro Fang; Kevin G Becker; Royce J Hamilton; Soumya Chigurupati; Yongqing Zhang; Josephine M Egan; Deborah L Croteau; David M Wilson; Mark P Mattson; Vilhelm A Bohr
Journal:  Nucleic Acids Res       Date:  2014-12-30       Impact factor: 16.971

5.  The therapeutic potential of mesenchymal stem cells in Alzheimer's disease: converging mechanisms.

Authors:  Gadi Turgeman
Journal:  Neural Regen Res       Date:  2015-05       Impact factor: 5.135

6.  Downregulation of human Wnt3 in gastric cancer suppresses cell proliferation and induces apoptosis.

Authors:  Hai-Sheng Wang; Xiaobo Nie; Rui-Bing Wu; Hong-Wei Yuan; Yue-Hong Ma; Xiu-Lan Liu; Jian-Yu Zhang; Xiu-Ling Deng; Qin Na; Hai-Yan Jin; Yan-Chao Bian; Yu-Min Gao; Yan-Dong Wang; Wei-Dong Chen
Journal:  Onco Targets Ther       Date:  2016-06-27       Impact factor: 4.147

7.  FOXG1 Directly Suppresses Wnt5a During the Development of the Hippocampus.

Authors:  Yang Ni; Bin Liu; Xiaojing Wu; Junhua Liu; Ru Ba; Chunjie Zhao
Journal:  Neurosci Bull       Date:  2021-01-03       Impact factor: 5.203

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.